Skip to Main Content


alt text

Yale University is one of six genetic research centers created by the National Institute of Diabetes, Digestive and Kidney diseases (NIDDK) seeking to advance the discovery of genes influencing an individuals’ risk for developing Crohn’s disease and ulcerative colitis.

Here at the Yale IBD Program, we believe research is an integral component of achieving the highest quality care. The Yale IBD Program is uniquely suited to offer state of the art research to the patients who are evaluated. Both clinicians and researchers work together for the patient’s best interest. For us, the goal of research is three-fold: to improve clinical therapy, to improve patient outcomes, and to increase our understanding of the disease. Our research interests and studies fall into two categories, Clinical and Translational. All research is approved through Yale Institutional Review Board (IRB).

Interested Participants

Research Contact

If you would like more information about our research studies, please contact our Clinical Trials Coordinator:

Elizabeth Ruggiero
Tel: (203) 785-7573 
Fax: (203) 737-1345

Frequently Asked Questions

Frequently Asked Questions

2. IBD Immune Responses

Understanding changes of immune responses and immune pathways in patients with IBD. The goals of these projects are to define changes in expression of genes, and in immunological pathways and responses in patients with Crohn's disease and ulcerative colitis by examining immune cells from the blood and intestine of patients with IBD. Requires a small blood sample.

Principal Investigators: Dr. Clara Abraham and (HIC # 0607001669) 

Status - Enrolling